Last reviewed · How we verify
NCT07429422
SBRT Technique Implementation for Spinal Metastases Irradiation
NA trial testing Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases in Spinal Metastases in 100 participants. Currently enrolling.
31 December 2022
Quick facts
| Lead sponsor | Institute of Oncology Ljubljana |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 November 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across Slovenia |
Drugs / interventions tested
- Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases
Conditions studied
- Spinal Metastases — all drugs for Spinal Metastases →
- Spinal Tumors — all drugs for Spinal Tumors →
- Bone Metastases — all drugs for Bone Metastases →
Sponsor
Institute of Oncology Ljubljana
Who can join
18 and older, any sex, with Spinal Metastases or Spinal Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stereotactic body radiotherapy (SBRT) is a highly precise, image-guided radiotherapy technique delivering 1-5 high-dose fractions to spinal metastases. Compared with conventional radiotherapy, SBRT enables delivery of a higher biologically effective dose while maintaining high precision. The Institute of Oncology Ljubljana initiated spinal SBRT treatments in 2017 and introduced an institutional SBRT spine protocol in 2019. As SBRT is technically demanding, strict adherence to standardized planning and delivery procedures is essential to ensure treatment quality and patient safety. This clinical program aims to support structured implementation and continuous development of the institutional SBRT spine protocol in routine clinical practice. The study prospectively evaluates treatment-related toxicity and local tumor control following SBRT for spinal metastases in order to monitor treatment safety and effectiveness within the institutional program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07429422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Metastases
Currently open trials in the same condition.
- NCT06548061 — D20054;LITT for Spine Tumors · NA · recruiting
- NCT06244264 — The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis · NA · recruiting
- NCT06120426 — En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor · recruiting
- NCT05575323 — Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases · NA · recruiting
- NCT04863612 — SBRT in the Management of Solid Spinal Metastases · recruiting
Other Institute of Oncology Ljubljana trials
Trials by the same sponsor.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07432399 — Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) · Phase 2 · recruiting
- NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
- NCT07420647 — Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment · NA · active not recruiting
- NCT07416500 — BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07429422 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Oncology Ljubljana
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07429422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing